106 related articles for article (PubMed ID: 36238838)
1. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
Tozuka Y; Ueno M; Kobayashi S; Morimoto M; Fukushima T; Sano Y; Kawano K; Hanaoka A; Tezuka S; Asama H; Moriya S; Morinaga S; Ohkawa S; Maeda S
Oncol Lett; 2022 Oct; 24(4):375. PubMed ID: 36238838
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Asama H; Ueno M; Kobayashi S; Fukushima T; Kawano K; Sano Y; Tanaka S; Nagashima S; Morimoto M; Ohira H; Maeda S
Pancreas; 2022 Feb; 51(2):148-152. PubMed ID: 35404889
[TBL] [Abstract][Full Text] [Related]
3. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Suzuki Y; Saito K; Nakai Y; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Takahara N; Tateishi R; Fujishiro M
Support Care Cancer; 2023 Mar; 31(3):197. PubMed ID: 36862196
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Hamada T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672308
[TBL] [Abstract][Full Text] [Related]
6. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.
Mita N; Iwashita T; Uemura S; Yoshida K; Iwasa Y; Ando N; Iwata K; Okuno M; Mukai T; Shimizu M
J Clin Med; 2019 May; 8(6):. PubMed ID: 31146420
[TBL] [Abstract][Full Text] [Related]
7. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Takeda T; Sasaki T; Suzumori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Int J Clin Oncol; 2021 Jul; 26(7):1293-1303. PubMed ID: 33791917
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.
Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q
Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584
[TBL] [Abstract][Full Text] [Related]
9. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T; Shirakawa T; Shimokawa M; Koga F; Kawaguchi Y; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Okabe Y; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Mizuta T; Mitsugi K; Ureshino N
Int J Clin Oncol; 2021 May; 26(5):941-950. PubMed ID: 33483857
[TBL] [Abstract][Full Text] [Related]
10. Low-dose gemcitabine plus nab-paclitaxel
Kamata K; Imai H; Matsumoto H; Yamashita Y; Kato T; Nishi K; Omoto S; Minaga K; Yamao K; Hyodo T; Im SW; Hara A; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Ueshima K; Chiba Y; Takenaka M; Watanabe T; Kitano M; Kudo M
JGH Open; 2023 Sep; 7(9):659-666. PubMed ID: 37744711
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma.
Pignon F; Turpin A; Hentic O; Coriat R; Salmon E; Baumgaertner I; Bertrand N; Lévy P; Rebours V; Hammel P; de Mestier L
Pancreatology; 2021 May; ():. PubMed ID: 34090806
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites.
Inoue K; Fukushi K; Yamaguchi S; Taira T; Shibuki T; Satake T; Watanabe K; Sasaki M; Imaoka H; Mitsunaga S; Ikeda M
Pancreatology; 2024 Jun; 24(4):616-623. PubMed ID: 38599956
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
14. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
16. Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer.
Sadaka S; Iwashita T; Fujii H; Kato-Hayashi H; Ohata K; Uemura S; Shimizu M; Suzuki A
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233762
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison.
Orlandi E; Citterio C; Anselmi E; Cavanna L; Vecchia S
Cancer Diagn Progn; 2024; 4(2):165-171. PubMed ID: 38434919
[TBL] [Abstract][Full Text] [Related]
19. Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Merza N; Farooqui SK; Dar SH; Varughese T; Awan RU; Qureshi L; Ansari SA; Qureshi H; Mcilvaine J; Vohra I; Nawras Y; Kobeissy A; Hassan M
World J Oncol; 2023 Oct; 14(5):325-339. PubMed ID: 37869244
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the G8 Geriatric Assessment Tool as a Prognostic Factor in Gemcitabine Plus Nab-paclitaxel Combination Therapy for Elderly Patients with Pancreatic Cancer.
Kadokura M; Mori Y; Takenaka Y; Yoda H; Yasumura T; Tanaka K; Amemiya F
JMA J; 2022 Oct; 5(4):512-519. PubMed ID: 36407075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
